Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | PYGM | P11217 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13743093 | 0.87 | DHODH (0.41) | DHODHHCAR2NR4A2 | |
| SCHEMBL1568450 | 0.84 | DHODH (0.40) | DHODHHCAR2NR4A2 | |
| SCHEMBL11462679 | 0.83 | — | — | |
| SCHEMBL29242587 | 0.81 | DHODH (0.53) | DHODHNR4A2 | |
| SCHEMBL31618472 | 0.75 | DHODH (0.34) | DHODH | |
| SCHEMBL2296442 | 0.67 | — | — | |
| SCHEMBL168735 | 0.67 | PYGM (0.35) | DHODHPYGM | |
| SCHEMBL11430568 | 0.67 | FFAR3 (0.36) | PYGM | |
| SCHEMBL1286030 | 0.67 | PYGM (0.35) | DHODHPYGM | |
| SCHEMBL1428318 | 0.67 | PYGM (0.35) | DHODHPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106674248-B | Synthesis process of cantharidin | 重庆市中药研究院 | 2019-02-26 | — | — | CN | claimed |
| CN-107827903-A | Prepare the reuse of cantharidin key reaction intermediate ion liquid | 重庆市中药研究院 | 2018-03-23 | — | — | CN | claimed |
| CN-106674248-A | Novel green environment-friendly synthesis process of cantharidin | 重庆市中药研究院 | 2017-05-17 | — | — | CN | claimed |
| EP-4339199-B1 | SYNTHESIS OF CANTHARIDIN | VERRICA PHARMACEUTICALS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12221452-B2 | Synthesis of cantharidin | VERRICA PHARMACEUTICALS INC. (US) | 2025-02-11 | — | — | US | disclosed |
| CN-118084861-A | Synthesis of cantharidin | 维里卡制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240109911-A1 | SYNTHESIS OF CANTHARIDIN | VERRICA PHARMACEUTICALS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| EP-4339199-A2 | SYNTHESIS OF CANTHARIDIN | Verrica Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-111819182-B | Synthesis of cantharidin | 维里卡制药有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-3692044-B1 | SYNTHESIS OF CANTHARIDIN | VERRICA PHARMACEUTICALS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3692044-B1 | SYNTHESIS OF CANTHARIDIN | VERRICA PHARMACEUTICALS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-106674248-B | Synthesis process of cantharidin | 重庆市中药研究院 | 2019-02-26 | — | — | CN | disclosed |
| US-20190002474-A1 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | VERRICA PHARMACEUTICALS INC. | 2019-01-03 | — | — | US | disclosed |
| US-20190002474-A1 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | VERRICA PHARMACEUTICALS INC. | 2019-01-03 | — | — | US | disclosed |
| CN-107827903-A | Prepare the reuse of cantharidin key reaction intermediate ion liquid | 重庆市中药研究院 | 2018-03-23 | — | — | CN | disclosed |
| EP-3233865-A2 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | Verrica Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| CN-106674248-A | Novel green environment-friendly synthesis process of cantharidin | 重庆市中药研究院 | 2017-05-17 | — | — | CN | disclosed |
| CN-106674248-A | Novel green environment-friendly synthesis process of cantharidin | 重庆市中药研究院 | 2017-05-17 | — | — | CN | disclosed |
| WO-2016100732-A2 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | VERRICA PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100732-A2 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | VERRICA PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109911-A1 | SYNTHESIS OF CANTHARIDIN | TYR, CMA1, DPM1 | DHODH 412/4885HCAR2 3741/4885NR4A2 3974/4885 |
| US-12221452-B2 | Synthesis of cantharidin | TYR, CMA1, DPM1 | DHODH 412/4885HCAR2 3741/4885NR4A2 3974/4885 |
| US-20190002474-A1 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | TYR, CHIA, NISCH | DHODH 473/4885HCAR2 1713/4885NR4A2 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.